Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Progress in human tumor immunology has recently been accelerated by new assays for antigen-specific cytotoxic T lymphocytes (CTLs). We have used tetrameric MHC class I complexes (tetramers) to study melanoma-specific CTLs both in vivo and in vitro, and have utilized the results to optimize vaccination strategies for patients. Tetramers have provided some of the best evidence to date that CTL responses against melanoma antigens arise spontaneously in patients. However, CTL responses to common (nonmutated) melanoma epitopes are generally weak or localized, and occur mostly in advanced metastatic disease, hence justifying early immunotherapeutic approaches. These observations led us to design a polyvalent vaccine construct for early administration to melanoma patients at high risk of progression. To compare possible vaccination protocols, we encoded this construct in several different vectors, and developed novel tetramers to track responses to the human melanoma epitopes in transgenic mice. Priming and boosting with the same poly-epitope construct encoded in heterologous vectors led to the expansion of CTLs with a single dominant specificity. Separating the antigens for independent presentation by antigen-presenting cells reversed the effect of immunodominance and induced a powerful polyvalent CTL response. These results provide important pointers for future vaccination trials, and tetramers will form an important tool in the immunomonitoring of these clinical studies.


Journal article


Immunol Rev

Publication Date





155 - 163


Animals, Antigen Presentation, Antigens, Neoplasm, Biopolymers, Cancer Vaccines, Clone Cells, Cytotoxicity, Immunologic, Epitopes, T-Lymphocyte, Genetic Vectors, HLA-A2 Antigen, Histocompatibility Antigens Class I, Humans, Immunodominant Epitopes, Immunologic Memory, Immunotherapy, Active, Lymphokines, MART-1 Antigen, Melanoma, Mice, Mice, Transgenic, Neoplasm Proteins, Peptide Fragments, T-Lymphocytes, Cytotoxic, Vaccines, Subunit, Vaccines, Synthetic